title: [Pregnancy (conception) in hyper- or hypothyroidism].
abstract: Pregnancy is accompanied by changes in thyroid function. Due to the increased synthesis of thyroid binding globulin and the thyroid-stimulating effect of human chorionic gonadotrophin (hCG), serum concentrations of thyroid hormones will increase in the first trimester of pregnancy (total T4, T3). Free T4 levels decrease during the latter half of pregnancy. Hyperthyroidism during pregnancy is usually due to Graves' disease. Definitive therapy may be considered for cases prior to pregnancy, although a medical management as would be given during pregnancy is an equally good option. The medical management of hyperthyroidism consists of a monotherapy with thyreostatics in which the recommended dose needs to be adjusted on the basis of free T4 in the high-normal and thyroid stimulating hormone (TSH) in the low-normal area so as to minimise the risk of foetal hypothyroidism. The transplacental passage of maternal TSH receptor stimulating antibodies may cause foetal hyperthyroidism. Another cause of maternal hyperthyroidism during pregnancy is 'gestational transient thyrotoxicosis', which is associated with high hCG levels during the first trimester of pregnancy. It is nearly always accompanied by hyperemesis gravidarum. Hypothyroidism in pregnancy has negative consequences for the foetus. If the hypothyroidism is apparent prior to pregnancy, it should be corrected before conception (target TSH value of 1 mU/l). If discovered during pregnancy, treatment with levothyroxine should be started as soon as possible. In the case of a pre-existing hypothyroidism a 25-50% increase in the levothyroxine dosage is often needed during the first trimester of pregnancy. This is possibly due to an increased requirement. An adequate serum concentration of T4 is necessary for foetal brain development.
authors.affiliation: Afd. Endocrinologie en Metabolisme, Academisch Medisch Centrum/Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam. e.p.corssmit@amc.uva.nl
authors.forename: E P
authors.initials: EP
authors.lastname: Corssmit
authors.forename: W M
authors.initials: WM
authors.lastname: Wiersinga
authors.forename: K
authors.initials: K
authors.lastname: Boer
authors.forename: M F
authors.initials: MF
authors.lastname: Prummel
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D019468:Disease Management; D004305:Dose-Response Relationship, Drug; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control*; D020249:Hormone Replacement Therapy; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D007037:Hypothyroidism / Q000175:diagnosis / Q000188:drug therapy*; D007231:Infant, Newborn; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D018566:Pregnancy, High-Risk; D011441:Propylthiouracil / Q000627:therapeutic use; D013960:Thyroid Function Tests; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D013956:Antithyroid Agents; D011441:Propylthiouracil; D013974:Thyroxine